Bioscript Group strengthens its service offering with the addition of Meridian HealthComms

Bioscript Group strengthens its service offering with the addition of Meridian HealthComms; giving significant scale to its medical communications, strategic planning and creative services capabilities.

The addition of Meridian HealthComms extends the depth of Bioscript Group’s growing healthcare communications services and builds on the acquisition of Fortis Pharma Consulting and Valid Insight in July 2021.

Macclesfield, UK – April, 2022 – Bioscript Group, the integrated, healthcare communication company, has today announced a strategic acquisition that further strengthens its medical communications offering.

Meridian HealthComms, which joins the Bioscript Group today, was founded in 2004 and has built enduring partnerships with its pharmaceutical and biotech clients through its strength in scientific and clinical communications, strategic planning and brand management. The newly combined business will be able to provide clients with extended support across integrated medical communication programmes from very early clinical development through to market access communications.

Bioscript Group is one of the largest independent global agencies, with a strong international reputation for high-quality medical communications, regulatory writing and market access consultancy. With this latest addition, Bioscript Group brings together more than 220 dedicated experts in healthcare communications globally with a focus on scientific and writing excellence, expert engagement, events management, strategic planning, and patient access consulting.

Andrew Medley, CEO of Bioscript Group, commented: “Our sector is seeing huge growth and we want to be the healthcare communications agency of choice for our clients and for our employees. Meridian joining our Group means we can continue to build our skills, capabilities services, as well as quickly widening the pool of clients we work with. Joining with other companies is part of our 5-year plan for growth.

Together, we see the potential for more effective end-to-end delivery across the entire lifecycle, from very early clinical development through to market access communications, meaning we can deliver a wider range of projects.

This is another important step on our growth journey as we will continue to expand our offering for our clients and team.”

He added: “With the strategic acquisitions completed last year and now the addition of Meridian, we are better placed than ever to provide specialist scientific and strategic expertise that supports our clients in delivering advances in patient care.”

Dave Andrews, MD of Meridian HealthComms, added: “We are delighted to be joining the Bioscript Group. Combined with greater medical communications resources, our clients now have access to a broader scope of expertise across regulatory writing, value comms and market access to allow integrated communications support throughout the product lifecycle.”

In March 2021, Bioscript Group announced significant new investment from Sovereign Capital Partners, to drive the next phase of its ambitious growth plan, significantly increasing its geographic footprint and extending into adjacent strategic services.